Evaluating the Effect of Polypharmacy on Outcomes in HIV-Infected Patients Age 50 and Older

  • Wilcox M
  • Cottreau J
  • Mancuso T
  • et al.
N/ACitations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background. Polypharmacy is associated with older age, medication administration errors, increased hospitalizations, poorer adherence, and increases in drug-drug interactions. The efficacy, pharmacokinetics, adverse effects, and potential drug-drug interactions (DDIs) of ART in older adults have not been systematically studied. This study will investigate associations between polypharmacy and HIV virologic suppression and other outcomes in older HIV-infected adults. Methods. This IRB-approved, retrospective cohort study evaluated outcomes in HIV-infected patients aged ≥ 50 years as of 1 June 2013 on ART and seen at least once at the Northwestern Infectious Disease Center between 1 June 2013-31 May 2015. Data were collected from the most recent encounter for each patient. Eligible patients were stratified by number of prescribed medications: ≥10 versus <10 medications. The primary outcome was detectable versus non-detectable plasma HIV RNA level (viral load; undetectable defined as at least one value <20 IU/mL). Secondary outcomes included DDIs, CD4+ T-lymphocyte count (cells/mm3, CD4), taking medications on the Beers List (potentially inappropriate medications for elderly patients), and patient reported adverse drug effects. Results. One hundred patients were included (≤ 10 medications, n = 65; >10 medications, n = 35). Baseline characteristics were similar between groups. Patients taking >10 medications had lower median CD4 counts (351 versus 561 cells/mm3; P < 0.01). Forty-eight patients taking ≤10 medications had a viral load <20 IU/mL compared to 21 participants on >10 medications (84.2% versus 67.7%, P = 0.07). Patients taking >10 medications were more likely to report an adverse event (45.7% versus 26.5%, P = 0.047), take medications on the Beers List (71.4% versus 41.5%; P < 0.01), and report DDIs (94.3% versus 67.7%; P < 0.01). All but one DDI was categorized as a ?potential DDI? (79 of 80). Conclusion. Patients taking >10 medications were no less likely to achieve HIV suppression than persons taking ≤10 medications; however, they were more likely to report a medication-related adverse effect. Further studies are needed to evaluate the impact of overall medication burden upon clinical outcomes in older HIV-infected persons.

Cite

CITATION STYLE

APA

Wilcox, M. L., Cottreau, J., Mancuso, T., Palella, F. J., Postelnick, M., & Mclaughlin, M. M. (2016). Evaluating the Effect of Polypharmacy on Outcomes in HIV-Infected Patients Age 50 and Older. Open Forum Infectious Diseases, 3(suppl_1). https://doi.org/10.1093/ofid/ofw172.1198

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free